Abstract Submission Guidelines f - ARVO

Abstracts must be submitted with the intention that the research described in the abstract will be the work that is
presented. If the abstract is accepted for presentation, the First Author must present the same work described in
the abstract, with the same title and content.
As part of their presentation, First Authors must reveal the essential structures (DNA sequences, molecules, etc.),
the elements of a novel compound and/or the sufficient identification of new gene compounds, if applicable.
An author whose abstract has been accepted is required to register and pay the Annual Meeting registration fee,
attend the Annual Meeting and make the presentation of the abstract.
A full-meeting complimentary exhibitor registration does not qualify as a paid registration for a Presenting Author.
Abstracts may be scheduled for presentation on any day of the 2014 ARVO Annual Meeting,
i.e., Sunday, May 4 through Thursday, May 8. Mark your calendar now for possible required
attendance on any one of these days!
Notification of individual abstract presentation scheduling will be sent to First Authors of
accepted abstracts on Tuesday February 18 th , 2014. Changes to the abstract presentation
schedule as determined by the AMPC cannot be accommodated.
Copyright Transfer
The required acknowledgement of the First Author, acting as the authorized agent for all authors, certifies: a) that
each contributing author has provided to the First Author a written transfer of copyright for the contributions he/she
has made to the abstract. *Such Copyright Transfer assigns copyright ownership for all contributions to this
abstract to the Association for Research in Vision and Ophthalmology (ARVO); or b) that this abstract is a work of
authorship prepared as part of the author's official duties as an officer or employee of the U.S. Government, and
is, therefore, in the public domain. Should the abstract be determined as copyrightable, all copyright ownership of
this abstract shall be conveyed to ARVO. *The signed copyright transfers from each co-author should be retained
and not mailed to the ARVO Office. Suggested wording for such a document is: I [author's name], an author
who has contributed to the abstract entitled [title of abstract], hereby transfer all my rights, title and interest in such
contribution (including the copyright) to ARVO [author's signature and date]. You can also use ARVO’s Copyright
Transfer Document for each of your co-authors.
Animals or Human Subjects Used in Research
The required acknowledgement of the First Author, acting as the authorized agent for all authors, certifies that any
research reported was conducted in compliance with the “ARVO Statement of the Use of Animals in Ophthalmic
and Visual Research” and/or the “Declaration of Helsinki”.
Abstract Rejection
The AMPC reserves the right to reject abstracts according to the Abstract Rejection Guidelines. Failure to comply
with all policies and guidelines will result in rejection of your abstract, at the sole discretion of the AMPC.
Abstract Publication
- Abstracts accepted for presentation will be published as submitted by the Dec. 8 deadline; no additions or
revisions will be published.
- ARVO will not make any changes to abstracts; no exceptions.
- Abstracts will be published in ARVO’s 2014 Mobile Application and Annual Meeting CD-ROM as well as
Investigative Ophthalmology and Visual Science (IOVS) online as the ARVO version of record.
- All abstracts not withdrawn by Friday, January 31 st , 2014, will be published.
2